Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes

被引:1
作者
Catelli, Chiara [1 ]
Faccioli, Eleonora [1 ]
Silvestrin, Stefano [1 ]
Lorenzoni, Giulia [2 ]
Luzzi, Luca [3 ]
Bennett, David [4 ]
Schiavon, Marco [1 ]
Campisi, Alessio [5 ]
Bargagli, Elena [4 ]
Dell'Amore, Andrea [1 ]
Rea, Federico [1 ]
机构
[1] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Thorac Surg Unit, I-35121 Padua, Italy
[2] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Unit Biostat Epidemiol & Publ Hlth, I-35121 Padua, Italy
[3] Univ Siena, Lung Transplant Unit, Azienda Osped Univ Senese, I-53100 Siena, Italy
[4] Univ Siena, Resp Dis & Lung Transplant Unit, Azienda Osped Univ Senese, I-53100 Siena, Italy
[5] Univ & Hosp Trust Borgo Trento, Dept Thorac Surg, I-37126 Verona, Italy
关键词
cancer; lung transplantation; survival; outcomes; FOLLOW-UP; PREEXISTING MALIGNANCIES; EXPLANTED LUNGS; CANCER; RECIPIENTS; HEART; CANDIDATES; REMISSION; MORTALITY; CHEST;
D O I
10.3390/cancers16030538
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Lung transplantation (LTX) is the treatment of choice for patients with end-stage lung disease but its role is still controversial in those with a history of malignancies. The aim of this study was to evaluate short- and long-term outcomes in patients submitted to LTX with a history of previous neoplasia or oncological disease detected in the native lung. Our study showed that this population had worse overall survival compared to a control group, emphasizing the importance of an accurate selection and a strict post-operative follow-up in this group of patients.Abstract The accurate selection of the recipient is a crucial aspect in the field of lung transplantation (LTX), especially if patients were previously affected by oncological disease. The aim of this bicentric retrospective study was to evaluate short- and long-term outcomes in patients with previous oncological disease or unknown neoplasia found on native lungs submitted to LTX, compared to a control group. A total of 433 patients were included in the analysis, 31 with malignancies (Group 1) and 402 without neoplastic disease (Group 2). The two groups were compared in terms of short- and long-term outcomes. Patients in Group 1 were older (median age 58 years vs. 50 years, p = 0.039) and mostly affected by idiopathic pulmonary fibrosis (55% vs. 40% p = 0.002). Even though in Group 1 a lower rate of late post-operative complications was found (23% vs. 45%, p = 0.018), the median overall survival (OS) was lower compared to the control group (10 months vs. 29 months, p = 0.015). LTX represents a viable therapeutic option for patients with end-stage lung disease and a history of neoplastic disease. However, every case should be carefully debated in a multidisciplinary setting, considering oncological (histology, stage, and proper disease free-interval) and clinical factors (patient's age and comorbidities). A scrupulous post-transplant follow-up is especially mandatory in those cases.
引用
收藏
页数:10
相关论文
共 27 条
  • [1] Incidence of primary neoplasms in explanted lungs: Long-term follow-up from 214 lung transplant patients
    Abrahams, NA
    Meziane, M
    Ramalingam, P
    Mehta, A
    DeCamp, M
    Farver, CF
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (09) : 2808 - 2811
  • [2] Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study
    Acuna, Sergio A.
    Sutradhar, Rinku
    Kim, S. Joseph
    Baxter, Nancy N.
    [J]. TRANSPLANTATION, 2018, 102 (07) : 1156 - 1164
  • [3] Outcomes of Solid Organ Transplant Recipients With Preexisting Malignancies in Remission: A Systematic Review and Meta-Analysis
    Acuna, Sergio A.
    Huang, Johnny W.
    Daly, Corinne
    Shah, Prakesh S.
    Kim, S. Joseph
    Baxter, Nancy N.
    [J]. TRANSPLANTATION, 2017, 101 (03) : 471 - 481
  • [4] Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
    Balestro, Elisabetta
    Cocconcelli, Elisabetta
    Tine, Mariaenrica
    Biondini, Davide
    Faccioli, Eleonora
    Saetta, Marina
    Rea, Federico
    [J]. MEDICINA-LITHUANIA, 2019, 55 (10):
  • [5] Pre-transplant malignancy: An analysis of outcomes after thoracic organ transplantation
    Beaty, Claude A.
    George, Timothy J.
    Kilic, Arman
    Conte, John V.
    Shah, Ashish S.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (02) : 202 - 211
  • [6] Overall and Cause-Specific Mortality in Transplant Recipients with a Pretransplantation Cancer History
    Brattstrom, Christina
    Granath, Fredrik
    Edgren, Gustaf
    Smedby, Karin E.
    Wilczek, Henryk E.
    [J]. TRANSPLANTATION, 2013, 96 (03) : 297 - 305
  • [7] Chambers DC, 2019, J HEART LUNG TRANSPL, V38, P1042, DOI 10.1016/j.healun.2019.08.001
  • [8] Incidental Lung Cancer of Explanted Lungs from Lung Transplant Recipients: Incidence, Characteristics, and 5-Year Survival
    Choi, Yong Jun
    Kim, Song Yee
    Park, Moo Suk
    Lee, Tin Gu
    Paik, Hyo Chae
    Lee, Sang Hoon
    [J]. YONSEI MEDICAL JOURNAL, 2020, 61 (11) : 958 - 964
  • [9] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Distler, Oliver
    Highland, Kristin B.
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen D.
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Tetzlaff, Kay
    Kuwana, Masataka
    Maher, Toby M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26) : 2518 - 2528
  • [10] Successful Lung Transplantation in a Patient With History of Lobectomy for Small Cell Lung Cancer: A Case Report
    Faccioli, Eleonora
    Dell'Amore, Andrea
    Schiavon, Marco
    Rea, Federico
    [J]. TRANSPLANTATION PROCEEDINGS, 2021, 53 (04) : 1382 - 1384